Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

University Of Zurich patents


Recent patent applications related to University Of Zurich. University Of Zurich is listed as an Agent/Assignee. Note: University Of Zurich may have other listings under different names/spellings. We're not affiliated with University Of Zurich, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "U" | University Of Zurich-related inventors


Novel compounds capable of antagonizing islet amyloid polypeptide (iapp) induced beta-cell damage and impaired glucose tolerance

Described are molecules specifically binding to human islet amyloid polypeptide (hiapp) also known as amylin, particularly human-derived antibodies as well as fragments, derivatives and variants thereof for antagonizing islet amyloid polypeptide (iapp) induced β-cell damage and impaired glucose tolerance which are symptoms typically associated with diabetes mellitus type 2 (t2d).. . ... University Of Zurich

Method of providing disease-specific binding molecules and targets

Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as alzheimer's disease are described.. ... University Of Zurich

Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases

Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of jc virus (jcv) and/or bk virus (bkv) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus vp1 and or polyomavirus vp1 virus-like particles (vlps), preferably of the type of jcv and/or bkv, are disclosed. ... University Of Zurich

Novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases

Methods for diagnosing inflammatory and/or cardiovascular diseases by assaying for fibroblast activation protein (fap) expression in a body fluid is provided as well as therapeutic means based thereon.. . ... University Of Zurich

Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof

Provided are novel human-derived antibodies specific for fibroblast activation protein (fap), preferably capable of selectively inhibiting the enzymatic activity of fap, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with fap are provided. ... University Of Zurich

Method of providing disease-specific binding molecules and targets

Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as alzheimer's disease are described.. ... University Of Zurich

Benzazepin-1-ol-derived pet ligands with high in vivo nmda specificity

The present invention is directed to benzazepin-1-ol-derived compounds for use in the diagnosis of nmda receptor-associated diseases or disorders by positron emission tomography (pet). The invention also relates to a method for the diagnosis of nmda-receptor-associated diseases or disorders by administering to a patient in need of such diagnosis a radioactively labelled compound of the invention in an amount effective for pet imaging of nmda receptors, recording at least one pet scan, and diagnosing an nmda-receptor-associated disease or disorder from an abnormal nmda receptor expression pattern on the pet scan. ... University Of Zurich

Tdp-43 specific binding molecules

Provided are novel tdp-43-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these tdp-43 specific binding molecules. ... University Of Zurich








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with University Of Zurich in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for University Of Zurich with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###